DNA monoclonal antibodies targeting checkpoint molecules
By administering recombinant nucleic acid sequences and electroporation technology targeting immune checkpoint molecules, the immune response is enhanced, and the problem of antigens in vaccines triggering weak immune responses is solved, and the therapeutic effect on cancer and infectious diseases is improved.
Patent Information
- Application Number
- CN202510540397.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2016-05-05
- Filing Date
- 2017-05-05
- Publication Date
- 2025-07-25
AI Technical Summary
In the prior art, vaccines have the problem of triggering a weak immune response to certain antigens when stimulating immune responses, and immune checkpoint molecules such as PD-1, CTLA-4, etc. negatively regulate the immune response in cancer and infectious diseases, resulting in immunosuppression.
The immune response, especially the CD8+ T cell response, is enhanced by administering a DNA plasmid containing a composition encoding a recombinant nucleic acid sequence targeting an immune checkpoint molecule, such as a DNA plasmid of PD-1, LAG-3, GITR, CD40, OX40, CTLA-4, TIM-3, 4-1BB antibody, in combination with electroporation technology.
It improves the immune response to antigen, enhances the cell lytic activity of CD8+ T cells and the secretion of the antiviral cytokine IFN-γ, and promotes the prevention and treatment of cancer and infectious diseases.